Drugmakers Argue Federal Law Preempts Pancreatic Cancer Claims

Federal law preempts the claims of plaintiffs alleging they were not adequately warned of the risk of pancreatic cancer from incretin-based drugs, several drugmakers said in court papers filed in federal multidistrict litigation.

YOUR COMPLIMENTARY 15-DAY LAW.COM TRIAL HAS ENDED.
Subscribe now to continue reading →

To continue reading, upgrade and become a Law.com subscriber.
Get 2 MONTHS FREE when you sign up for a 12 month subscription.